I. Executive Summary

Coloplast A/S is a global medical technology company and a market leader in the development and sale of products for intimate healthcare needs. The company holds a dominant #1 global market position in its core Chronic Care segments of Ostomy Care and Continence Care, which are characterized by non-discretionary patient demand, high customer loyalty, and stable, recurring revenue streams. This foundation has historically enabled Coloplast to deliver consistent, above-market organic growth and industry-leading profitability.

The company is currently in the midst of a significant strategic transformation, defined by its “Strive25” strategy and a new long-term plan extending to 2030. This evolution involves a pivot towards a dual-engine growth model. While continuing to innovate and gain share in its mature, high-margin core businesses, Coloplast has deployed significant capital on major acquisitions to establish new growth platforms. The 2022 acquisition of Atos Medical created a new Voice and Respiratory Care segment, and the 2023 acquisition of Kerecis has strategically repositioned the company in the high-growth biologics segment of the Advanced Wound Care market. These moves have raised the company’s long-term organic growth ambition from 7-9% to 8-10% annually.¹

Financially, this strategic shift has materially altered the company’s profile. The acquisitions were largely debt-financed, significantly increasing leverage and causing a substantial decline in Return on Invested Capital (ROIC) from historical levels above 40% to 15% in fiscal year 2023/24.³ While the core business remains highly profitable, the initial margin-dilutive effect of the acquisitions has compressed the group’s best-in-class EBIT margin from over 30% to a guided 27-28% for fiscal year 2024/25.⁴

Recent performance has been impacted by a confluence of challenges, including a product recall in Interventional Urology, a slowdown and product return in China, and adverse currency movements, which prompted a downward revision to the company’s 2024/25 growth guidance.⁶ Furthermore, the company is navigating a CEO transition and a major executive restructuring designed to manage its increased operational complexity.⁶ The external environment also presents material risks, most notably a recent proposal by the U.S. Centers for Medicare & Medicaid Services (CMS) to include core product categories in competitive bidding programs, posing a long-term threat of price erosion in a key growth market.⁸

Despite these headwinds, Coloplast’s underlying business model remains robust, supported by powerful demographic tailwinds and a deep competitive moat built on innovation, brand strength, and high switching costs. The company continues to trade at a significant valuation premium to its peers, a reflection of its historical quality and growth prospects. The central investment question is whether the successful execution of its ambitious M&A integration and the long-term potential of its new growth platforms can justify this premium valuation amidst a period of heightened operational complexity, increased financial leverage, and emerging regulatory risks.

II. Company Overview and Business Model

Coloplast A/S is a Danish multinational company that develops, manufactures, and markets medical devices and services related to ostomy, urology, continence, wound, and skin care. Founded in 1954, the company’s mission is to “make life easier for people with intimate healthcare needs”.³ It operates globally, serving over two million users across 140 countries with a workforce of approximately 16,500 employees.³

Core Business Segments

As of fiscal year 2023/24, Coloplast operates across five distinct business segments, which were recently organized under two broader commercial units—Chronic Care and Acute Care—to better reflect their different market dynamics and patient pathways.⁸

• Chronic Care: This unit comprises the company’s historical foundation and largest revenue contributors.

• Ostomy Care: This segment provides products for people with a stoma (an artificial opening in the abdomen), including ostomy bags, baseplates, and supporting accessories like seals and adhesive removers. Key product lines include the SenSura® Mio portfolio.³ In FY 2023/24, this segment generated DKK 9.5 billion in revenue.³
• Continence Care: This segment addresses bladder and bowel dysfunction with products such as intermittent catheters, collecting devices (urine bags), and bowel management solutions. The SpeediCath® and the new Luja™ intermittent catheter portfolios are the primary drivers of this business.³ It generated DKK 8.5 billion in revenue in FY 2023/24.³
• Voice and Respiratory Care: Established through the 2022 acquisition of Atos Medical, this segment serves patients who have undergone a laryngectomy (removal of the voice box) or have a tracheostomy. Products include voice prostheses and heat and moisture exchangers (HMEs) under the Provox® brand.³ This segment generated DKK 2.1 billion in revenue in FY 2023/24.³
• Acute Care: This unit includes businesses that are typically more hospital-centric and technologically driven.

• Advanced Wound Care: This segment offers solutions for the treatment of difficult-to-heal wounds. It is comprised of two main parts: Advanced Wound Dressings, featuring the Biatain® product line, and Biologics, which was established with the 2023 acquisition of Kerecis and its innovative fish-skin-based technology.¹ The combined segment generated DKK 4.1 billion in revenue in FY 2023/24.³
• Interventional Urology: This segment provides single-use surgical devices and implantables for urological and gynecological procedures. It includes products for Men’s Health (e.g., Titan® penile implants), Women’s Health, Endourology, and Bladder Health.³ It generated DKK 2.8 billion in revenue in FY 2023/24.³

Revenue Mix and Geographic Diversification

Coloplast’s revenue is well-diversified by business segment and geography, though it maintains a strong concentration in its core Chronic Care businesses and European markets.

Revenue by Business Area (FY 2023/24) ³

• Ostomy Care: 35%
• Continence Care: 31%
• Advanced Wound Care: 15%
• Interventional Urology: 10%
• Voice and Respiratory Care: 8%

Revenue by Geography (FY 2023/24) ³

• European Markets: DKK 14.8 billion (55% of total revenue), with 6% organic growth.
• Other Developed Markets (USA, Canada, Japan, Australia, New Zealand): DKK 7.7 billion (28% of total revenue), with 8% organic growth.
• Emerging Markets: DKK 4.5 billion (17% of total revenue), with 15% organic growth.

This geographic split highlights a reliance on the mature, stable European market, but also demonstrates the significant and faster-growing contribution from Emerging Markets, which is a key pillar of the company’s growth strategy.

Business Model and Value Proposition

Coloplast’s commercial model is fundamentally user-centric and built on a direct-to-consumer engagement strategy that creates a powerful competitive advantage. The model is based on five key pillars ³:

1. Clinically Differentiated Products: A focus on R&D to create innovative products that address unmet clinical needs and raise the standard of care. Examples include the Luja™ catheter designed to reduce the risk of UTIs and the Heylo™ digital leakage notification system for ostomy users.³
2. Building Clinical Preference: Partnering with healthcare professionals (HCPs) through education and support platforms like Coloplast® Professional, which had around 30,000 sign-ups in 2023/24, to establish its products as the preferred clinical choice.³
3. Building Consumer Preference: Engaging directly with end-users through personalized support programs. The flagship program, Coloplast® Care, provides education, product samples, and dedicated advisor support to patients, fostering loyalty and improving outcomes. The program is available in over 30 markets.³
4. Building Payer Preference: Using clinical studies and health economic data to document the value of its products, ensuring market access and favorable reimbursement levels from public and private payers.³
5. Documenting Value Through Data: Underpinning the entire model is a commitment to generating robust clinical and real-world data that validates the efficacy and economic benefits of its solutions.³

This model effectively transforms Coloplast from a simple medical device manufacturer into a more integrated healthcare solutions provider. The emphasis on patient support is not merely a marketing function but a core element of its value proposition. By building a direct relationship with the end-user, Coloplast creates an ecosystem that is difficult for competitors to replicate, as the competition is not just on product features but on the holistic service and support provided. The success of this model is evidenced by studies showing that the Coloplast® Care program can reduce 30-day hospital readmission rates by 30% and ER visits by 45% for ostomy patients, a powerful value proposition for the entire healthcare system.¹²

Recurring Revenue and Customer Stickiness

A defining characteristic of Coloplast’s business is the high quality and predictability of its revenue streams. The majority of its products, particularly in the Chronic Care segments, address lifelong conditions. This creates an annuity-like revenue stream from each patient, as they require a continuous supply of products.

This recurring revenue is protected by high customer switching costs. These costs are not primarily financial but are rooted in user habit, clinical trust, and the integrated support system. Once a patient is comfortable with a specific product and integrated into the Coloplast® Care support network, the incentive to switch to a competitor’s product—which may have a different application process or feel—is very low. This “stickiness” is a cornerstone of Coloplast’s economic moat and allows for stable market share and pricing power. The recent acquisitions of Atos Medical and Kerecis represent a strategic test of this business model’s transferability. While the “intimate healthcare” model was perfected in Ostomy and Continence Care, its application to the different patient pathways and reimbursement structures of laryngectomy and biologics wound care is not guaranteed. The company’s recent strategic reorganization into distinct Chronic and Acute Care divisions is a direct acknowledgment of this challenge, aiming to apply the appropriate commercial model to each unique market.⁸

III. Industry Dynamics and Market Position

Coloplast operates in several large, structurally growing segments of the medical technology market. These markets are underpinned by powerful, long-term demographic and healthcare trends, and are characterized by a rational competitive environment in which Coloplast holds a leading position.

Market Analysis by Segment

Coloplast estimates its total addressable market to be worth DKK 110-120 billion, with an estimated underlying growth rate of 4-5% per year.¹⁰ This growth is driven by an aging global population and expanding healthcare coverage, particularly in emerging markets.

• Ostomy Care: The global market for ostomy care products and accessories is valued at approximately USD 3.6 billion to USD 3.9 billion in 2024, with various market research firms projecting a compound annual growth rate (CAGR) in the range of 4.3% to 5.5% through the end of the decade.¹⁴ Key drivers include the increasing incidence of colorectal cancer, inflammatory bowel diseases (IBD) like Crohn’s disease and ulcerative colitis, and a growing geriatric population that is more susceptible to these conditions.¹⁵
• Continence Care: This is a significantly larger market, with 2024 size estimates ranging from USD 17.8 billion to USD 19.7 billion.¹⁸ The market is forecast to grow at a robust CAGR of 5.7% to 7.5%.¹⁹ This growth is fueled by the high prevalence of urinary incontinence, which affects a large portion of the aging population, as well as rising awareness and destigmatization of the condition, leading more individuals to seek treatment.²¹
• Advanced Wound Care: The global market for advanced wound care is valued between USD 11.3 billion and USD 21.0 billion in 2024, with projected CAGRs of 4.8% to 7.0%.²³ This market is driven by the increasing prevalence of chronic wounds, such as diabetic foot ulcers, pressure ulcers, and venous leg ulcers, which are often associated with chronic diseases like diabetes and obesity.²⁵ The biologics sub-segment, where Coloplast’s recent acquisition Kerecis operates, is a particularly high-growth area within this market.

Demographic Tailwinds

The long-term outlook for all of Coloplast’s key markets is supported by powerful and non-cyclical demographic trends:

• Aging Global Population: The proportion of the global population over the age of 60 is projected to increase from 10% in 2022 to 16% by 2050.¹⁹ This demographic shift is a primary driver for Coloplast, as the incidence of incontinence, colorectal cancer, and chronic wounds increases significantly with age.²¹
• Rising Prevalence of Chronic Diseases: Global trends of rising obesity and diabetes are direct catalysts for market growth. Diabetes, in particular, is a major cause of chronic wounds (diabetic foot ulcers) and can also lead to bladder control issues, driving demand for both wound care and continence care products.¹⁹

Competitive Positioning and Market Share

The competitive landscape in Coloplast’s core markets is best described as a stable oligopoly.

• Market Structure: The Chronic Care markets of ostomy and continence care are dominated by three main global players: Coloplast, ConvaTec Group PLC, and the privately-held U.S. company Hollister Incorporated.²⁸ This rational market structure contributes to stable pricing and high industry-wide profitability.
• Coloplast’s Market Position: Coloplast is the clear global market leader. It holds the #1 position in both Ostomy Care, with an estimated global market share of 35-40%, and in Continence Care.³ The company’s market share is strongest in its home region of Europe, where it commands 40-50% of the market. Its share in other developed markets, most notably the U.S., is significantly lower at 15-25%.³ This disparity represents both a historical challenge and the company’s single largest opportunity for future organic growth.
• Key Competitors:

• ConvaTec Group PLC (LON:CTEC): A UK-based company with annual revenues of approximately USD 2.3 billion, ConvaTec is a formidable competitor across Advanced Wound Care, Ostomy Care, and Continence Care.³¹ The company is actively innovating, with recent product launches such as the Esteem Body™ ostomy system and the GentleCath™ line of catheters, competing directly with Coloplast’s flagship products.¹⁹
• Hollister Incorporated: A privately-owned American company that is a major force in Ostomy Care and Continence Care. Hollister is particularly known for its focus on skin health, with its CeraPlus™ line of products infused with ceramide being a key differentiator.³⁴ As a private entity, its financial details are not public, but it is considered to roughly split the non-Coloplast share of the ostomy market with ConvaTec.²⁸
• B. Braun Melsungen AG: A large, diversified, family-owned German medical technology company with annual sales of approximately €8.8 billion.³⁶ While B. Braun competes in wound and ostomy care, it has a much broader portfolio of hospital supplies and surgical instruments, making it a less specialized competitor in Coloplast’s core niches.³⁸

Competitive Advantages (Economic Moat)

Coloplast has built a wide and durable economic moat around its business, primarily stemming from intangible assets and high customer switching costs.²⁸

• Intangible Assets: The Coloplast brand is synonymous with quality and reliability among clinicians and patients. This reputation, built over more than 60 years, is a powerful intangible asset. It is further protected by a portfolio of patents on its innovative product designs and technologies.
• Switching Costs: As previously detailed, the costs for a patient to switch from a Coloplast system are significant. They involve not just learning a new product but also leaving the established support ecosystem of the Coloplast® Care program. This creates a powerful incumbency advantage and customer loyalty that is difficult for competitors to overcome on price or features alone.
• Scale and Distribution: A global manufacturing footprint and an established distribution network provide economies of scale and broad market access, creating a barrier to entry for smaller, regional players.

The competitive dynamic in these markets is evolving from a focus on individual product features to a broader competition between entire ecosystems. While product innovation remains essential, the company that can provide the most comprehensive and effective wrap-around service of patient support, digital tools, and clinical education is best positioned to gain market share over the long term. Coloplast, with its mature and clinically validated Coloplast® Care program, appears to have a significant head start in this ecosystem-based competition.

IV. Financial Performance Analysis

Coloplast has a long history of delivering strong financial results, characterized by consistent above-market growth and industry-leading profitability. However, the recent strategic shift towards growth through major acquisitions has fundamentally altered its financial profile, most notably impacting returns on capital and balance sheet leverage.

Historical Financial Review (FY 2019/20 – 2023/24)

An analysis of the company’s performance over the past five fiscal years reveals a clear inflection point corresponding with the launch of its “Strive25” strategy and the acquisitions of Atos Medical and Kerecis.

Table 1: Coloplast A/S Five-Year Financial Highlights (DKK million)

Income Statement (DKK million)	2023/24	2022/23	2021/22	2020/21	2019/20
Revenue	27,030	24,500	22,579	19,426	18,544
Organic Growth (%)	8	8	6	7	4
Operating Profit (EBIT) before special items	7,286	6,845	6,910	6,355	5,854
Operating Margin (EBIT margin) before special items (%)	27	28	31	33	32
Net profit for the year	5,052	4,783	4,706	4,825	4,197
Balance Sheet (DKK million)
Total assets	48,073	48,159	37,446	15,841	13,499
Net interest-bearing debt (NIBD)	21,841	18,660	18,091	2,112	1,162
Equity at year end	17,942	17,299	8,292	8,168	7,406
Cash Flows (DKK million)
Cash flows from operating activities	2,766	4,226	5,099	5,290	4,759
Free cash flow	1,430	-4,731	-6,660	3,279	3,858
Key Ratios
Gearing ratio (NIBD/EBITDA before special items)	2.5	2.4	2.3	0.3	0.2
Return on average invested capital after tax (ROIC, %)	15	17	27	45	46
Return on equity (%)	31	59	64	70	66
Source: Coloplast A/S Annual Report 2023/24 3

• Revenue Growth: Revenue has grown at a compound annual growth rate (CAGR) of approximately 7.9% over the five-year period, from DKK 18.5 billion to DKK 27.0 billion. Organic growth has been remarkably consistent, ranging between 4% and 8% annually, consistently outpacing the underlying market growth of 4-5%.³
• Profitability: A key trend is the compression of the EBIT margin before special items, which has declined from a peak of 33% in FY 2020/21 to 27% in FY 2023/24. This is primarily a result of the inclusion of the Kerecis acquisition, which is initially margin-dilutive by approximately 100 basis points, as well as the impact of higher input cost inflation in recent years.³ Despite this compression, a 27% EBIT margin remains at the top end of the medical technology industry.

Key Financial Metrics Analysis

The most significant change in Coloplast’s financial story is the impact of its M&A strategy on its balance sheet and return metrics.

• Return on Invested Capital (ROIC): The dramatic decline in ROIC is the single most important financial metric illustrating the company’s strategic transformation. ROIC after tax has fallen from a world-class 46% in FY 2019/20 to a more modest, though still respectable, 15% in FY 2023/24.³ This is not due to a collapse in profitability, but rather a massive increase in the “Invested Capital” denominator of the calculation. The acquisitions of Atos Medical and Kerecis added significant amounts of goodwill and intangible assets to the balance sheet, fundamentally changing the company’s capital structure. Coloplast has effectively traded its exceptional historical capital efficiency for higher long-term growth prospects. The investment case now hinges on management’s ability to grow the acquired businesses and extract synergies to drive this ROIC figure higher over time.
• Debt Levels and Gearing: To fund its acquisitions, Coloplast has taken on significant debt. Net interest-bearing debt has surged from just DKK 1.2 billion in FY 2019/20 to DKK 21.8 billion in FY 2023/24. Consequently, the gearing ratio (NIBD/EBITDA) has increased from a negligible 0.2x to 2.5x.³ While this is a manageable level of leverage, it represents a fundamental shift from a net-cash or low-debt company to one with a more conventional leveraged balance sheet.
• Cash Generation: Cash flow from operating activities has remained robust, although it was lower in FY 2023/24 due to an extraordinary tax payment related to the Atos Medical IP transfer.³⁹ Free cash flow has been highly volatile, turning significantly negative in FY 2021/22 and FY 2022/23 due to the cash outflows for the Atos Medical acquisition and related investments.³

Segment and Geographic Performance Deep Dive

The underlying performance of the business segments remains strong.

• Growth Drivers: The Chronic Care business remains the stable engine, with Ostomy Care delivering 7% organic growth and Continence Care delivering 8% in FY 2023/24.³ The new growth platforms are performing well, with Voice and Respiratory Care growing 11% and Advanced Wound Care growing 10% organically.³ Geographically, Emerging Markets were the standout performer with 15% organic growth, highlighting the long-term potential in these regions.³
• Margin Stability: The ability to maintain a group EBIT margin of 27-28% despite the dilutive impact of acquisitions, inflationary pressures, and supply chain challenges points to the formidable underlying profitability and pricing power of the core Chronic Care business. This core business likely operates at a margin profile well above 30%, which provides a crucial financial cushion that enables the company to absorb the integration costs and lower initial profitability of its new growth platforms. This financial strength affords management the time and resources needed for its M&A strategy to mature and deliver value.

V. Growth History and Future Opportunities

Coloplast’s growth strategy is a well-defined combination of consistent organic execution in its core markets and transformative acquisitions to enter new, high-growth adjacencies. This dual approach is designed to extend the company’s growth runway for the long term.

Historical Organic Growth vs. Market

Coloplast has a distinguished track record of outperforming its end markets. While the underlying markets for its products grow at an estimated 4-5% annually, Coloplast has consistently delivered organic growth in the 7-8% range.³ This sustained outperformance is a testament to its ability to continuously gain market share through product innovation and a superior commercial model. This historical consistency provides a strong foundation of credibility for its future growth ambitions.

Innovation Pipeline and R&D

Innovation is a cornerstone of Coloplast’s strategy, with R&D expenditures consistently maintained at approximately 3-4% of revenue, amounting to DKK 913 million in FY 2023/24.³ The company’s innovation philosophy is centered on developing “clinically differentiated products” that offer tangible improvements in patient outcomes, which in turn supports premium pricing and drives adoption among clinicians and patients.³

Key recent and upcoming innovations include:

• Luja™ Intermittent Catheter: Launched in 2023 for men and expanded to women in 2024, the Luja™ catheter features a unique “Micro-hole Zone Technology.” Clinical data has shown it enables more complete bladder emptying, which is a key factor in reducing the risk of Urinary Tract Infections (UTIs).³ This product is a primary growth driver in the Continence Care segment.³⁹
• Heylo™ Digital Leakage Notification System: Launched in the UK in 2024, Heylo™ is a digital device for ostomy users that provides an alert before a leak occurs.³ This represents a significant step into the digital health space, aiming to improve quality of life and reduce patient anxiety.
• Advanced Wound Care and Ostomy Portfolio Expansion: Recent launches include Biatain® Silicone Fit, a new dressing for the U.S. market, and an expansion of the flagship SenSura® Mio ostomy line with new convexity options and a discreet black bag.³

Acquisition Strategy and Integration

Under its “Strive25” strategy, Coloplast has explicitly embraced M&A as a core pillar for growth, executing a classic “core and explore” strategy. It is leveraging the stable, predictable cash flows from its dominant “core” Chronic Care business to fund transformative acquisitions in adjacent, higher-growth “explore” areas.

• Atos Medical (Acquired Jan 2022 for EUR 2.16 billion): This acquisition established the Voice and Respiratory Care business unit, providing Coloplast with an entry into a new chronic care market with a global leadership position, limited competition, and significant untapped growth potential.³ The business is targeted to deliver sustained 8-10% growth.⁷
• Kerecis (Acquired Aug 2023 for up to USD 1.3 billion): This was a strategic move to fundamentally upgrade Coloplast’s position in the Advanced Wound Care market by entering the high-growth biologics segment.¹ Kerecis possesses a unique and patented technology platform based on intact fish skin, which has demonstrated superior wound healing in clinical trials.³⁹ Kerecis is expected to grow at a three-year CAGR of approximately 30% and is central to Coloplast’s ambition to become a leader in this space.³

The Kerecis acquisition, in particular, represents more than just a purchase of revenue; it is a high-risk, high-reward bet on a disruptive technology platform. Success hinges on the continued validation of the fish-skin technology’s clinical superiority, which could allow Coloplast to disrupt a market long dominated by incumbents. The positive results from the recent Odinn randomized controlled trial (RCT) provide crucial early validation for this strategic bet.⁴¹ As a direct result of these acquisitions, Coloplast raised its long-term organic growth guidance from a 7-9% range to an 8-10% range, signaling confidence in these new platforms.¹

Key Growth Drivers and Potential Headwinds

• Future Growth Drivers:

• U.S. Market Penetration: With a market share of only 15-25% compared to 40-50% in Europe, the U.S. remains the single largest organic growth opportunity for the core Chronic Care business.³
• Emerging Markets Expansion: These markets are growing at a mid-teens rate (15% in FY 2023/24) and offer a long runway for growth as healthcare access and standards of living improve.³
• Commercialization of Acquired Platforms: The successful global rollout of Atos Medical’s products and the expansion of Kerecis beyond its U.S.-centric base are critical drivers for achieving the new long-term growth targets.
• Potential Headwinds:

• Execution Risk: The simultaneous integration of two large and strategically different businesses carries significant execution risk.
• Market-Specific Challenges: Recent performance has been hampered by a slowdown in China and a product recall in Interventional Urology, highlighting the vulnerability to localized issues.⁵
• Reimbursement Pressure: The potential for adverse reimbursement changes, particularly in the U.S., remains a persistent headwind for the entire industry.

VI. Capital Allocation Strategy

Coloplast’s capital allocation strategy is guided by a dynamic process aimed at maximizing long-term value creation. Management’s stated priorities are, first, to reinvest in the business through commercial initiatives and R&D; second, to pursue value-accretive M&A; and third, to return excess capital to shareholders.² The recent period has been defined by a significant deployment of capital towards M&A.

Dividend Policy and Share Buyback Programs

Coloplast is committed to returning excess liquidity to its shareholders, with a formal policy targeting a dividend payout ratio of 60-80% of the group’s net profit.³

• Dividend History: The company has a long track record of paying a consistent and growing dividend. The total dividend per share has increased each year from DKK 18.0 in FY 2019/20 to a proposed DKK 22.0 for FY 2023/24.³
• Recent Payouts: For the 2023/24 fiscal year, the proposed total dividend of DKK 22.00 per share represents a payout ratio of 98% (after special items).³ This is notably above the top end of the target range and signals a strong commitment to shareholder returns, even in a period of high investment and deleveraging. Based on recent share prices, the forward dividend yield is estimated to be in the range of 1.6% to 3.6%.⁴⁵

Share buybacks are also part of the capital return framework, though the focus has recently been on dividends and debt reduction following the large acquisitions.³

M&A and Capital Deployment Efficiency

The acquisitions of Atos Medical (EUR 2.16 billion) and Kerecis (up to USD 1.3 billion) represent the most significant capital deployments in the company’s modern history.¹¹ This has fundamentally shifted the balance sheet, and a primary focus of capital allocation in the near term is now on integration and deleveraging. Management has a stated target of bringing the gearing ratio (NIBD/EBITDA) back down to its target range of 1-2x.³ This focus on repairing the balance sheet suggests that further large-scale M&A is unlikely in the immediate future. The tension between the aggressive M&A strategy and the generous dividend policy is evident in the stretched balance sheet, implying that future free cash flow will be prioritized for debt repayment.

CAPEX Investments

Capital expenditures are a key part of reinvesting in the business to support organic growth and improve efficiency. For FY 2024/25, CAPEX is expected to be approximately DKK 1.4 billion, in line with the long-term target of 4-6% of revenue.³⁹

Key investment areas include ³:

• Manufacturing Footprint Expansion: A crucial de-risking strategy involves diversifying production away from the heavy concentration in Hungary. This includes the continued ramp-up of two sites in Costa Rica and a major investment of around DKK 700 million in a new, large-scale manufacturing facility in Portugal, which is expected to be operational in 2026.
• Automation and Efficiency: Investments in new machinery, automation, and IT infrastructure to support growth and maintain cost competitiveness.
• Integration: CAPEX related to the integration of Atos Medical onto Coloplast’s global platforms.

This significant investment in manufacturing diversification, while costly, is a prudent long-term strategy to build a more resilient and robust global supply chain, mitigating the risks associated with single-country dependency.

VII. Recent Developments and Challenges (2023-2025)

The recent period has been one of significant change and challenge for Coloplast, marked by a major leadership transition, strategic restructuring, operational issues, and the emergence of new regulatory risks in its most important growth market.

Management and Strategic Changes

• CEO Transition: In May 2025, it was announced that CEO Kristian Villumsen was stepping down from his role, with Lars Rasmussen, a seasoned executive, appointed as interim CEO.⁶ The search for a new permanent CEO is ongoing.⁵ This change introduces a degree of leadership uncertainty during a critical period of integrating the company’s largest-ever acquisitions.
• Executive Leadership Restructuring: In August 2025, Coloplast announced a significant reorganization of its Executive Leadership Team. The key change was the creation of two distinct business units: Chronic Care (comprising Ostomy, Continence, and Voice & Respiratory Care) and Acute Care (comprising Interventional Urology and a new combined Wound & Tissue Repair unit).⁸ This restructuring is a direct response to the increased complexity of the business post-acquisitions, aiming to create more focused commercial and R&D organizations tailored to the different market dynamics of each segment.

Operational and Market Challenges

Several operational and market-specific issues have created headwinds for the company, leading to a revision of its financial guidance for the 2024/25 fiscal year.

• Interventional Urology Product Recall: The Interventional Urology segment was negatively impacted by a product recall in its Bladder Health and Surgery business. The recall had a direct negative revenue impact of approximately DKK 35 million in Q2 and DKK 10 million in Q3 of FY 2024/25.⁵ More significantly, the subsequent recovery in sales has been much slower than anticipated, forcing the company to revise the full-year growth outlook for the segment to around 0%.⁶
• China Headwinds: Performance in China, a key emerging market, has been challenging. The company has experienced a general slowdown in growth and was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings. This product return was expected to have a negative revenue impact of around DKK 80 million in the second half of the fiscal year.⁵
• FY 2024/25 Guidance Revision: As a direct result of the slower recovery in Interventional Urology and higher uncertainty in China and other emerging markets, Coloplast revised its full-year 2024/25 guidance in May 2025. The organic growth forecast was lowered from 8-9% to approximately 7%, and the EBIT margin guidance was adjusted from “around 28%” to a range of 27-28%.⁶

Regulatory Environment (U.S. Focus)

In July 2025, the U.S. Centers for Medicare & Medicaid Services (CMS) issued two separate draft proposals with significant potential implications for Coloplast’s business.

• Competitive Bidding Proposal: CMS proposed that medical supplies for ostomy, tracheostomy, and urology could be subjected to competitive bidding programs in the future.⁸ This represents a material long-term risk, as competitive bidding typically leads to significant price erosion. Coloplast’s U.S. Chronic Care business represents about 12% of group sales.⁸ While the company is analyzing the potential impact, it has stated that any financial effect would not be felt before 2027 at the earliest.⁸
• Skin Substitute Payment Proposal: In a separate rule, CMS proposed a new fixed payment structure for skin substitutes used in the outpatient setting.⁸ Coloplast has assessed this proposal as a net positive for its Kerecis business. The proposed payment rate is favorable compared to the current average price of Kerecis’s products in this setting, and the move could increase access and quality of care for patients.⁸

These two proposals highlight the dual reality of the U.S. healthcare market: constant pressure for cost containment on mature product categories, alongside a willingness to provide favorable reimbursement for innovative technologies that demonstrate superior clinical outcomes. This dynamic validates Coloplast’s strategy of investing in high-end innovation (Kerecis) to offset the inevitable long-term pricing pressure in its more established product lines.

The confluence of the CEO departure, major restructuring, operational stumbles, and significant new regulatory proposals creates a period of heightened uncertainty and elevates the execution risk for Coloplast in the near-to-medium term.

VIII. Competitive Landscape Evolution

The competitive environment for Coloplast is dynamic, characterized by rational competition among established peers in its core markets and an emerging focus on technological and digital innovation as a new frontier for differentiation.

Recent Strategic Moves by Competitors

While the oligopolistic structure of the Chronic Care markets remains intact, key competitors are not standing still. They continue to innovate and compete for market share through new product launches and strategic initiatives.

• ConvaTec: Has been particularly active in launching new products that compete directly with Coloplast’s portfolio. In 2024, the company launched its Esteem Body with Leak Defense ostomy system in Europe, featuring soft convexity for a better fit.¹⁶ It also launched the GentleCath Air for Women catheter in the UK and Italy, targeting a key user group in the continence care market.¹⁹
• Hollister Incorporated: Has focused on strengthening its brand positioning around skin health. In January 2024, its CeraPlus ostomy products received global dermatological accreditation from the Skin Health Alliance, a key marketing differentiator.⁴⁹ The company also announced a USD 25 million investment to expand its manufacturing capabilities in Lithuania in February 2023, signaling a commitment to growth.⁴⁹
• Wound Care Competition: The advanced wound care space remains highly competitive. Smith & Nephew launched its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) system in April 2024, and 3M launched a new V.A.C. peel and place dressing in September 2024, indicating continued R&D investment from major players in this segment.²⁴

This activity suggests a rational competitive dynamic focused on incremental product innovation, brand building, and service, rather than disruptive price wars. This structure is a key reason for the industry’s historically attractive and stable profitability.

Technological Disruption

A significant evolution in the competitive landscape is the shift towards digital health solutions and “smart” devices. The goal is to move beyond passive products to systems that can provide data, monitor patients, and enable proactive care.

• Coloplast’s Heylo™: Coloplast’s launch of the Heylo™ digital leakage notification system is a prime example of this trend.³ It aims to address one of the biggest sources of anxiety for ostomy patients and represents a move to capture value in the digital service layer, not just the physical product.
• Broader Industry Trend: This shift is not unique to Coloplast. The broader wound care market is seeing the emergence of smart bandages with sensors to detect inflammation and AI-based tools to aid in wound diagnosis and monitoring.⁵⁰

The real long-term disruptive threat in these markets may not come from the traditional competitors, but from technology-native companies that could develop a superior sensor, data analytics platform, or patient engagement application. Such a development could commoditize the physical device (the bag or catheter) while capturing the high-margin value in the digital service. Coloplast’s early move with Heylo™ can be seen as both an offensive and defensive strategy to establish a leading position in this emerging space.

Pricing and Reimbursement Challenges

Pricing pressure is a constant and evolving challenge across all of Coloplast’s markets, driven by government and private payer efforts to contain healthcare costs. The most significant recent development is the U.S. CMS proposal to include ostomy and urology supplies in competitive bidding programs.⁸ This has the potential to fundamentally alter the pricing landscape in the world’s largest healthcare market and remains a key long-term risk for the entire industry.

IX. Operational Excellence and Innovation

Coloplast’s long-term success has been built on a foundation of operational excellence and a deeply ingrained culture of innovation. These remain key pillars of its strategy as it navigates a more complex business environment.

Manufacturing Efficiency and Supply Chain Optimization

“Unparalleled efficiency” is a core theme of the company’s Strive25 strategy, with a focus on creating a more resilient and cost-effective global supply chain.

• Global Operations Plan 6: This is the company’s strategic framework for its manufacturing and supply chain. A central element is the diversification of its manufacturing footprint to reduce its heavy reliance on its facilities in Hungary, which currently account for about 70% of production volumes.³ To mitigate risks related to labor availability and inflation in that region, Coloplast has made significant investments in new sites in Costa Rica and Portugal. The new DKK 700 million facility in Portugal is on track to be operational in 2026 and will be the company’s largest site to date.³ This geographical diversification is a costly but critical long-term investment in supply chain resilience.
• Cost Management and Synergies: In response to the high inflationary environment, Coloplast has initiated a company-wide procurement program to drive cost efficiencies, which is expected to benefit the cost base starting in FY 2024/25.⁴¹ Additionally, the integration of Atos Medical is on track to deliver up to DKK 100 million in run-rate operational synergies from leveraging shared infrastructure.⁷

Digital Transformation Initiatives

Digital technology is increasingly being integrated into Coloplast’s products and services to enhance the user experience and create new value.

• Digital Products: The launch of the Heylo™ digital leakage notification device is the company’s most prominent move into connected devices, aiming to transform the patient experience in ostomy care.⁴¹
• Patient and Clinician Engagement: The Coloplast® Care program is a key digital and service-based platform for engaging directly with patients. It continues to scale successfully, enrolling over 270,000 new users in FY 2023/24.³ For healthcare professionals, the Coloplast® Professional online platform provides education and resources, enhancing the company’s partnership with clinicians.³

Sustainability Initiatives

Sustainability is a strategic priority for Coloplast, with ambitious 2025 targets integrated into its business operations. The company reports transparently on its progress in its annual report.

• Reducing Emissions: Coloplast is committed to a 100% reduction in Scope 1 & 2 (direct) emissions by 2030, validated by the Science Based Targets initiative (SBTi). As of FY 2023/24, it had achieved a 27% reduction from its 2018/19 baseline. It also aims for 100% renewable energy by 2025 and was at 83% in FY 2023/24.³
• Improving Products and Packaging: The company has set 2025 goals for 90% of its packaging to be recyclable and 80% to be made from renewable materials. As of FY 2023/24, it had reached 74% and 68%, respectively, indicating progress but also that more work is needed.⁵² These initiatives could become a competitive advantage as healthcare systems and consumers place greater emphasis on environmental impact.
• Responsible Operations: Coloplast exceeded its 2025 goal for recycling production waste, reaching 77% in FY 2023/24 against a target of 75%.⁵² The company also maintains a high employee engagement score of 8.2 (out of 10), which is ahead of the healthcare industry benchmark of 7.7, reflecting a strong corporate culture.⁷

Brand Strength and Customer Satisfaction

Coloplast’s brand is one of its most valuable assets. The company’s “listen and respond” approach to innovation, which involves close collaboration with end-users and clinicians, has fostered a deep sense of trust and loyalty.⁵³ This is reflected in high patient satisfaction scores and the strong uptake of its support programs, which reinforce the brand’s reputation for being a true partner in managing intimate healthcare needs.⁴³

X. Valuation Analysis

Coloplast has consistently commanded a premium valuation relative to its medical technology peers, a reflection of its superior historical growth, profitability, and return on capital. The central question for investors is whether this long-standing premium is justified in light of the company’s evolving strategic and financial profile.

Historical Valuation Multiples

An examination of Coloplast’s historical valuation reveals a consistent pattern of trading at high multiples of its earnings and cash flow.

• Price-to-Earnings (P/E) Ratio: Over the last decade, Coloplast’s year-end P/E ratio has frequently been in the 35x to 50x range. As of the end of fiscal year 2024, the P/E ratio was 39.0x. More recent trailing-twelve-month (TTM) P/E ratios as of August 2025 are in the range of 32x to 36x.⁴⁶
• Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: This multiple, which accounts for debt, has also been elevated. It peaked at 32.6x in September 2020 and has since moderated, with recent figures ranging from approximately 20x to 27x.⁵⁵

This history of premium multiples indicates that the market has long recognized Coloplast as a high-quality “compounder” stock, willing to pay a higher price for its predictable growth and profitability.

Peer Benchmarking

When benchmarked against its direct competitors and the broader medical device industry, Coloplast’s premium valuation becomes starkly apparent.

Table 2: Valuation and Profitability Metrics – Peer Comparison (As of August 2025)

Metric	Coloplast A/S (COLO B)	ConvaTec Group PLC (CTEC)	Smith & Nephew PLC (SNN)	Becton, Dickinson and Co (BDX)
Valuation Multiples
P/E Ratio (Normalized)	31.8x	17.5x	18.3x	12.2x (EV/EBITDA)
Price/Sales Ratio	4.9x	2.6x	2.8x	N/A
EV/EBITDA Ratio	19.8x	16.7x	11.5x	12.2x
Profitability & Return Metrics
Return on Equity (Normalized)	30.1%	19.7%	14.7%	N/A
Return on Invested Capital (Normalized)	13.4%	12.7%	10.1%	N/A
Interest Coverage	8.8x	5.2x	4.5x	N/A
Source: Compiled from Morningstar, Investing.com 46(Note: BDX data for P/E, P/S, ROE, ROIC not directly comparable in sources, EV/EBITDA used for valuation context)

The data clearly illustrates the valuation gap. Investors are paying a P/E multiple for Coloplast that is nearly double that of its closest peers, ConvaTec and Smith & Nephew. The table also reveals the justification for this premium: Coloplast’s profitability and returns are demonstrably superior. Its 30.1% Return on Equity is significantly higher than its peers, and its interest coverage is more robust. Investors are paying a premium price for a premium-quality business.

Yield Analysis

• Dividend Yield: With a policy of returning 60-80% of net profit to shareholders, Coloplast offers a respectable dividend. As of August 2025, its forward dividend yield is estimated in a wide range of 1.6% to 3.6%, depending on the share price and dividend forecast used.⁴⁵
• Free Cash Flow (FCF) Yield: Based on FY 2023/24 FCF of DKK 1.43 billion and a market capitalization of approximately DKK 137 billion, the historical FCF yield is low at around 1.0%.³ This yield is currently suppressed by high capital expenditures for manufacturing expansion and the financial impacts of recent acquisitions.

Valuation Context

Coloplast’s premium valuation is a double-edged sword. It is a testament to the market’s appreciation for its durable competitive advantages, consistent growth, and high profitability. However, it also creates a high bar for performance. The margin for error is slim, and any failure to meet growth expectations or any significant operational misstep could lead to a de-rating of the stock’s multiple. A contraction of the P/E ratio from the low 30s towards the high teens where its peers trade would result in significant share price underperformance, even if the underlying business continues to grow.

Furthermore, the current macroeconomic environment of higher interest rates makes long-duration growth stocks like Coloplast particularly sensitive. The present value of their future cash flows is more heavily discounted in a higher-rate world, which could exert sustained pressure on the premium multiples the company has historically enjoyed.

XI. Risk Assessment

An investment in Coloplast involves a range of business, financial, and operational risks. The nature of these risks has evolved significantly with the company’s strategic shift towards M&A-fueled growth, increasing the overall complexity and execution dependency of the investment case.

Business and Strategic Risks

• M&A Integration Risk: This is currently the most significant strategic risk. The successful integration of Atos Medical and, particularly, Kerecis is paramount to achieving the company’s long-term growth targets. Failure to realize the expected revenue growth and synergies from these large and complex acquisitions would undermine the core rationale for the strategic shift and the capital deployed.
• Regulatory and Reimbursement Risk: The U.S. healthcare market is both the company’s largest growth opportunity and a major source of risk. The CMS proposal to include ostomy and urology products in competitive bidding programs poses a material, long-term threat to pricing power and profitability in the core Chronic Care business.³ Any adverse changes to reimbursement for Kerecis’s biologics products would also be a significant blow.
• Competitive Risk: While the competitive environment is rational, it remains intense. Competitors like ConvaTec and Hollister are actively innovating, and Coloplast must continue to invest in R&D to maintain its product leadership and defend its market share, especially in the critical U.S. market.³
• Innovation Risk: The company’s premium pricing and market leadership are predicated on its ability to deliver a continuous pipeline of innovative, clinically superior products. A failure in the R&D pipeline could lead to product commoditization, price erosion, and a loss of competitive advantage.³

Financial Risks

• Valuation Risk: As detailed previously, Coloplast’s stock trades at a substantial premium to its peers. This high valuation creates a significant risk of multiple compression (de-rating) if the company fails to meet the market’s high growth and profitability expectations.
• Debt and Leverage Risk: The acquisitions have increased net debt to DKK 21.8 billion and the gearing ratio to 2.5x NIBD/EBITDA.³ This increased leverage makes the company’s earnings more sensitive to interest rate fluctuations and reduces its financial flexibility for further large-scale M&A until the balance sheet is deleveraged.
• Currency Exposure: With a majority of its revenue generated outside of Denmark, Coloplast’s reported financial results are subject to significant currency fluctuations, particularly movements in the USD and EUR against the Danish Krone. Recent USD weakness, for example, has been a headwind to reported DKK revenue growth.⁵

Operational and Governance Risks

• Supply Chain and Manufacturing Risk: Coloplast has a significant concentration of its manufacturing in Hungary. While the company is actively mitigating this risk by investing in new facilities in Costa Rica and Portugal, any major disruption at its key sites could have a severe impact on its ability to supply products globally.³ The recent operational challenges in establishing a new U.S. distribution center highlight the complexity of managing a global supply chain.³⁹
• Management Transition Risk: The ongoing search for a permanent CEO following the departure of Kristian Villumsen creates leadership uncertainty at a pivotal moment for the company.⁶ The new leadership will be tasked with overseeing the complex integration of Atos and Kerecis while navigating a challenging external environment.
• Product Quality and Safety Risk: As a medical device manufacturer, Coloplast is exposed to the risk of product defects, recalls, and liability claims. A major quality issue could result in significant financial costs and damage to the company’s strong brand reputation.³

These risks are interconnected. For instance, a failure in M&A integration (strategic risk) would lead to lower-than-expected earnings, making it harder to service the debt (financial risk) and likely triggering a contraction in the high valuation multiple (valuation risk). The risk profile of Coloplast has fundamentally shifted from one dominated by product-level competition to one where strategic execution, capital discipline, and regulatory outcomes are the primary determinants of future success.

XII. Investment Thesis Framework

This framework synthesizes the preceding analysis into a balanced summary of the key attributes and challenges associated with an investment in Coloplast A/S. It outlines the core arguments for both a bullish and bearish perspective on the company’s stock at its current valuation.

Summary of Strengths (Bull Case)

• Market Leadership in Defensive Niches: Coloplast holds a dominant #1 global position in the structurally attractive markets of ostomy and continence care. These markets are characterized by non-discretionary demand, low cyclicality, and long-term growth driven by demographic tailwinds, providing a stable and predictable foundation for the business.
• High-Quality Business Model and Economic Moat: The company’s business model, centered on recurring revenue from chronic conditions, is protected by a wide economic moat. This moat is built on the strength of its brand, intangible assets from decades of innovation, and, most importantly, high customer switching costs reinforced by its direct-to-consumer support ecosystem (Coloplast® Care).
• Superior Profitability and Historical Returns: Coloplast consistently delivers industry-leading EBIT margins, even after recent compression. Historically, it has generated exceptional returns on invested capital, demonstrating a culture of operational excellence and disciplined execution.
• New Long-Term Growth Platforms: The strategic acquisitions of Atos Medical and Kerecis have added two new, high-growth businesses. These platforms significantly extend the company’s growth runway beyond its mature core markets and have led to an upward revision of its long-term growth ambition to 8-10%. Kerecis, in particular, offers the potential for disruptive technological leadership in the biologics wound care segment.
• Shareholder-Friendly Capital Allocation: The company has a strong track record of returning excess capital to shareholders through a consistent and growing dividend, supported by a clear payout policy.

Primary Concerns (Bear Case)

• Extreme Premium Valuation: The stock consistently trades at a significant premium to its peers on nearly every valuation metric (P/E, P/S, EV/EBITDA). This valuation implies a high degree of confidence in future execution and leaves very little margin for error. Any disappointment in growth or profitability could trigger a significant multiple compression, leading to share price underperformance.
• M&A Integration and Execution Risk: Coloplast is undertaking the largest and most complex business integrations in its history. The success of the Atos Medical and Kerecis acquisitions is not guaranteed and requires flawless execution. The recent CEO transition and executive restructuring add to the uncertainty during this critical period.
• Strained Balance Sheet and Altered Financial Profile: The acquisitions have transformed the company’s financial profile, moving from a low-debt, high-ROIC “compounder” to a more leveraged platform company. The balance sheet is more strained, financial flexibility is reduced in the near term, and the return on invested capital has been materially diluted.
• Regulatory and Pricing Pressure: The potential for the implementation of competitive bidding for core products in the U.S. represents the single largest external threat to the long-term profitability of the Chronic Care business. This risk, combined with general pricing pressures from healthcare systems globally, could erode the high margins that fund the company’s growth investments.

Sustainability of Competitive Advantages

The competitive advantages in the core Chronic Care business appear highly durable and sustainable, rooted in the deep incumbency advantages and high switching costs of its user base. In the newer segments, the advantages are less proven. For Atos Medical, the advantage lies in its market-leading position in a niche chronic market, which aligns well with Coloplast’s expertise. For Kerecis, the sustainability of its advantage will depend on its ability to protect its unique fish-skin technology platform through patents and continued clinical validation to maintain its differentiation against larger wound care competitors.

Concluding Risk-Reward Profile

An investment in Coloplast A/S presents a clear trade-off. On one hand, it offers exposure to a best-in-class global leader in defensive healthcare markets with a proven track record of execution and newly acquired platforms that promise an extended runway for high-single-digit growth. On the other hand, investors are required to pay a substantial premium for this quality at a time when the company’s operational complexity, financial leverage, and external risk profile have demonstrably increased. The long-term risk-reward balance will be determined by the new management team’s ability to successfully execute its ambitious integration and growth strategy, thereby validating the premium valuation that the market has historically and continues to award the company.

Works cited

1. Coloplast completes the acquisition of Kerecis, accessed August 29, 2025, https://www.coloplast.com/siteassets/investors/results-reports–presentations/20222023/coloplast-completes-the-acquisition-of-kerecis.pdf
2. “Capital allocation should be a dynamic process” | Deloitte Denmark, accessed August 29, 2025, https://www.deloitte.com/dk/en/services/financial-advisory/perspectives/capital-allocation-should-be-a-dynamic-process.html
3. Annual Report 2023/24 – Coloplast, accessed August 29, 2025, https://www.coloplast.com/siteassets/investors/corporate-governance/07_2024_annual_report_2023-24.pdf
4. Coloplast A/S – Interim Financial Report, 9M 2024/25 | Nasdaq, accessed August 29, 2025, https://www.nasdaq.com/press-release/coloplast-s-interim-financial-report-9m-2024-25-2025-08-19
5. Coloplast A/S – Interim Financial Report, 9M 2024/25 – GlobeNewswire, accessed August 29, 2025, https://www.globenewswire.com/news-release/2025/08/19/3135834/0/en/Coloplast-A-S-Interim-Financial-Report-9M-2024-25.html
6. Coloplast A/S – Announcement no. 04/2025 – Interim Financial Report, H1 2024/25, accessed August 29, 2025, https://www.biospace.com/press-releases/coloplast-a-s-announcement-no-04-2025-interim-financial-report-h1-2024-25
7. H1 2024/25 Coloplast roadshow presentation, accessed August 29, 2025, https://www.coloplast.com/siteassets/investors/latest-results/q2-202425/h1_2024-25_roadshow_presentation.pdf
8. Coloplast A/S (CLPBY.DK) – Public now, accessed August 29, 2025, https://docs.publicnow.com/viewDoc.aspx?filename=49767\EXT\7DFD588798895A44E9DF236CFF259355F8A214E1_780225DABE7CBE6A0D58B13A9384EBD6C0631E36.PDF
9. Coloplast, accessed August 29, 2025, https://www.coloplast.com/
10. Investing in Coloplast, accessed August 29, 2025, https://www.coloplast.com/investor-relations/investing-in-coloplast/
11. Coloplast announces agreement to acquire Atos Medical, accessed August 29, 2025, https://ml-eu.globenewswire.com/Resource/Download/2ef46e21-83f3-48f2-b3bb-e2f1204f2a53
12. Innovation in ostomy care – Coloplast, accessed August 29, 2025, https://www.coloplast.ca/ostomy/professional/clinical-resources/
13. Improved Outcomes – Coloplast US, accessed August 29, 2025, https://www.coloplast.us/landing-pages/composer-standardpageus/
14. Stoma Care Market Size And Global Industry Forecast 2026 – MarketsandMarkets, accessed August 29, 2025, https://www.marketsandmarkets.com/Market-Reports/ostomy-care-accessories-market-267183143.html
15. Ostomy/Stoma Care Market: Size, Trends & Forecast to 2034, accessed August 29, 2025, https://www.polarismarketresearch.com/industry-analysis/ostomy-care-market
16. Ostomy Care Bags Market Size, Share, Trend Analysis by 2033 – Emergen Research, accessed August 29, 2025, https://www.emergenresearch.com/industry-report/ostomy-care-bags-market
17. Global Ostomy Products and Accessories Market $5.7 Billion by 2031, accessed August 29, 2025, https://www.ihealthcareanalyst.com/global-ostomy-products-accessories-market/
18. Continence Care Market Size & Share Report, 2025 – 2034, accessed August 29, 2025, https://www.gminsights.com/industry-analysis/continence-care-market
19. Continence Care Market Size, Share & Trends Report, 2030 – Grand View Research, accessed August 29, 2025, https://www.grandviewresearch.com/industry-analysis/continence-care-market-report
20. Continence Care Market | Global Analysis Report 2031, accessed August 29, 2025, https://www.transparencymarketresearch.com/continence-care-market.html
21. Continence Care Products Market Size, Drivers | Forecast – 2032, accessed August 29, 2025, https://www.alliedmarketresearch.com/continence-care-products-market-A117370
22. Incontinence Care Products Market Growth, Drivers, and Opportunities – MarketsandMarkets, accessed August 29, 2025, https://www.marketsandmarkets.com/Market-Reports/incontinence-care-products-ipc-market-71950351.html
23. Advanced Wound Care Market Size | Industry Report, 2030, accessed August 29, 2025, https://www.grandviewresearch.com/industry-analysis/advanced-wound-care-market
24. Wound Care Market Size, Share, Trends & Growth Report, 2032 – Fortune Business Insights, accessed August 29, 2025, https://www.fortunebusinessinsights.com/wound-care-market-103268
25. Wound Care Market Growth, Drivers, and Opportunities – MarketsandMarkets, accessed August 29, 2025, https://www.marketsandmarkets.com/Market-Reports/wound-care-market-371.html
26. Wound Care Market Size, Share, Growth | CAGR Of 5.2%, accessed August 29, 2025, https://market.us/report/wound-care-market/
27. Incontinence And Ostomy Care Products Market Report 2030 – Grand View Research, accessed August 29, 2025, https://www.grandviewresearch.com/industry-analysis/incontinence-and-ostomy-care-products-industry
28. Nordic Stocks With a Wide Moat, accessed August 29, 2025, https://global.morningstar.com/en-nd/stocks/nordic-stocks-with-wide-moat
29. Ostomy Care Market Size, Growth Trends & Global Industry Analysis, 2030, accessed August 29, 2025, https://www.mordorintelligence.com/industry-reports/ostomy-care-market
30. Disposable Ostomy Bags: Global Market Review 2022-2024 and – GlobeNewswire, accessed August 29, 2025, https://www.globenewswire.com/news-release/2025/04/30/3071069/28124/en/Disposable-Ostomy-Bags-Global-Market-Review-2022-2024-and-Industry-Forecast-2025-2030-Featuring-Strategic-Financial-Profiles-of-Key-Players-Coloplast-Group-Hollister-Convatec-Group.html
31. About Us – Get Company Overview Here – Convatec, accessed August 29, 2025, https://www.convatec.com/about-us/
32. ConvaTec Group (LON:CTEC) Revenue – Stock Analysis, accessed August 29, 2025, https://stockanalysis.com/quote/lon/CTEC/revenue/
33. Convatec – Solutions for Management of Chronic Conditions, accessed August 29, 2025, https://www.convatec.com/
34. Hollister Incorporated | Ostomy, Continence, Wound & Critical Care | Hollister, accessed August 29, 2025, https://hollister.hartmann.info/
35. Hollister Incorporated US | Ostomy, Continence, and Critical Care | Hollister US, accessed August 29, 2025, https://www.hollister.com/en
36. B. Braun – Wikipedia, accessed August 29, 2025, https://en.wikipedia.org/wiki/B._Braun
37. B. Braun drives innovation in health care while sales and profit improved, accessed August 29, 2025, https://firstwordhealthtech.com/story/5839429
38. B. Braun Melsungen AG Company Profile – GlobalData, accessed August 29, 2025, https://www.globaldata.com/store/report/b-braun-melsungen-ag/
39. Coloplast A/S – Full-Year Financial Results 2023/24 – BioSpace, accessed August 29, 2025, https://www.biospace.com/press-releases/coloplast-a-s-full-year-financial-results-2023-24
40. Press releases – Coloplast, accessed August 29, 2025, https://www.coloplast.com/news-and-media/press-releases/
41. Coloplast roadshow presentation, accessed August 29, 2025, https://www.coloplast.com/siteassets/investors/fy_2023-24_rs_presentation.pdf
42. Coloplast announces agreement to acquire Kerecis and raises long-term growth expectations, accessed August 29, 2025, https://www.kerecis.com/coloplast-announces-agreement-to-acquire-kerecis-and-raises-long-term-growth-expectations/
43. Creating value with performance management Coloplast – Beyond Budgeting Institute, accessed August 29, 2025, https://bbrt.org/wp-content/uploads/bb-case-study.pdf
44. Investment calculator and dividend – Coloplast, accessed August 29, 2025, https://www.coloplast.com/investor-relations/investor-tools/investment-calculator/
45. www.digrin.com, accessed August 29, 2025, https://www.digrin.com/stocks/detail/COLO-B.CO/#:~:text=The%20forward%20dividend%20yield%20for,past%20three%20years%20is%205.27%25.
46. Coloplast AS Class B (COLO B) – Morningstar, accessed August 29, 2025, https://www.morningstar.com/stocks/xcse/colo%20b/quote
47. Coloplast launches new 2025 strategy and provides new long-term financial guidance of 7- 9% organic revenue growth and an EBIT margin of more than 30% – Danish-UK Association, accessed August 29, 2025, https://dkuk.org/news/coloplast-launches-new-2025-strategy-and-provides-new-long-term-financial-guidance-of-7-9-organic-revenue-growth-and-an-ebit-margin-of-more-than-30/
48. Announcements & News – Coloplast, accessed August 29, 2025, https://www.coloplast.com/investor-relations/announcements-and-news/
49. Ostomy Care And Accessories Market | Industry Report, 2030 – Grand View Research, accessed August 29, 2025, https://www.grandviewresearch.com/industry-analysis/stoma-care-ostomy-care-accessories-market
50. Wound Care Market Focused Insights 2024-2029, with Competitive Analysis of Key Vendors 3M, B. Braun, Cardinal Health, Convatec, Medtronic, Molnlycke Health Care, Smith & Nephew, Coloplast & More – ResearchAndMarkets.com – Business Wire, accessed August 29, 2025, https://www.businesswire.com/news/home/20250115829598/en/Wound-Care-Market-Focused-Insights-2024-2029-with-Competitive-Analysis-of-Key-Vendors-3M-B.-Braun-Cardinal-Health-Convatec-Medtronic-Molnlycke-Health-Care-Smith-Nephew-Coloplast-More—ResearchAndMarkets.com
51. U.S. Wound Care Centers Market Expands to USD 25.27 Billion by 2034, accessed August 29, 2025, https://www.towardshealthcare.com/insights/us-wound-care-center-market-sizing
52. Targets and reporting – Coloplast, accessed August 29, 2025, https://www.coloplast.com/sustainability/targets-and-reporting/
53. Contact Us – Coloplast, accessed August 29, 2025, https://www.coloplast.us/about-us/contact-us/
54. P/E ratio for Coloplast (COLO-B.CO) – Companies Market Cap, accessed August 29, 2025, https://companiesmarketcap.com/coloplast/pe-ratio/
55. Coloplast A/S (DB:CBH) EV / EBITDA – Investing.com, accessed August 29, 2025, https://www.investing.com/pro/DB:CBH/explorer/ev_to_ebitda_ltm
56. ConvaTec Group PLC (CTEC) – Morningstar, accessed August 29, 2025, https://www.morningstar.com/stocks/xlon/ctec/quote